Format

Send to

Choose Destination
Oncotarget. 2015 Dec 1;6(38):40443-51. doi: 10.18632/oncotarget.6217.

Linking estrogen receptor β expression with inflammatory bowel disease activity.

Author information

1
Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy.
2
Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy.
3
Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
4
Digestive Endoscopy Unit, Catholic University, Rome, Italy.
5
Gastroenterology and Digestive Endoscopy, Nuovo Regina Margherita Hospital, Rome, Italy.
6
Histopathology Complex Unit, Santo Spirito Hospital, Rome, Italy.
7
IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy.

Abstract

Crohn disease (CD) and ulcerative colitis (UC) are chronic forms of inflammatory bowel disease (IBD) whose pathogenesis is only poorly understood. Estrogens have a complex role in inflammation and growing evidence suggests that these hormones may impact IBD pathogenesis. Here, we demonstrated a significant reduction (p < 0.05) of estrogen receptor (ER)β expression in peripheral blood T lymphocytes from CD/UC patients with active disease (n = 27) as compared to those in remission (n = 21) and healthy controls (n = 29). Accordingly, in a subgroup of CD/UC patients undergoing to anti-TNF-α therapy and responsive to treatment, ERβ expression was higher (p < 0.01) than that observed in not responsive patients and comparable to that of control subjects. Notably, ERβ expression was markedly decreased in colonic mucosa of CD/UC patients with active disease, reflecting the alterations observed in peripheral blood T cells. ERβ expression inversely correlated with interleukin (IL)-6 serum levels and exogenous exposure of both T lymphocytes and intestinal epithelial cells to this cytokine resulted in ERβ downregulation. These results demonstrate that the ER profile is altered in active IBD patients at both mucosal and systemic levels, at least in part due to IL-6 dysregulation, and highlight the potential exploitation of T cell-associated ERβ as a biomarker of endoscopic disease activity.

KEYWORDS:

Immune response; Immunity; Immunology and Microbiology Section; T lymphocytes; cytokines; estrogen receptors; inflammation; inflammatory bowel disease

PMID:
26497217
PMCID:
PMC4747344
DOI:
10.18632/oncotarget.6217
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center